Perrigo/$PRGO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Perrigo
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Ticker
$PRGO
Sector
Primary listing
NYSE
Employees
8,379
Headquarters
Dublin, Ireland
Website
Perrigo Metrics
BasicAdvanced
$3.1B
-
-$0.58
0.47
$1.13
5.14%
Price and volume
Market cap
$3.1B
Beta
0.47
52-week high
$30.93
52-week low
$21.03
Average daily volume
1.9M
Dividend rate
$1.13
Financial strength
Current ratio
2.322
Quick ratio
1.006
Long term debt to equity
85.014
Total debt to equity
81.656
Interest coverage (TTM)
2.36%
Profitability
EBITDA (TTM)
863.8
Gross margin (TTM)
35.73%
Net profit margin (TTM)
-1.85%
Operating margin (TTM)
12.39%
Effective tax rate (TTM)
157.54%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
3.26%
Return on equity (TTM)
-1.32%
Valuation
Price to revenue (TTM)
0.719
Price to book
0.69
Price to tangible book (TTM)
-1.98
Price to free cash flow (TTM)
12.579
Free cash flow yield (TTM)
7.95%
Free cash flow per share (TTM)
1.793
Dividend yield (TTM)
5.02%
Forward dividend yield
5.14%
Growth
Revenue change (TTM)
-2.31%
Earnings per share change (TTM)
-36.40%
3-year revenue growth (CAGR)
-0.14%
3-year earnings per share growth (CAGR)
-12.64%
3-year dividend per share growth (CAGR)
4.59%
What the Analysts think about Perrigo
Analyst ratings (Buy, Hold, Sell) for Perrigo stock.
Bulls say / Bears say
Adjusted diluted EPS surged 106.9% year-over-year to $0.60 in Q1 2025, driven by expanded margins and lower interest expense, underscoring strong earnings leverage (Perrigo Q1 Release).
Management reaffirmed full-year 2025 adjusted EPS guidance of $2.90–$3.10 (13%–21% growth), showing confidence in delivering steady earnings growth amid market uncertainty (Perrigo Q2 Release).
On May 31, 2025, the U.S. FDA approved and Perrigo launched a store-brand version of Flonase (fluticasone propionate nasal spray), expanding its respiratory care product line and strengthening its national brand position (Reuters).
Organic net sales dropped 0.4% in Q1 and were flat at -0.1% in Q2 2025, indicating continued weakness in consumer demand and persistent pricing challenges across core OTC categories (Perrigo Q1 Release) (Perrigo Q2 Release).
In the North America Consumer Self-Care Americas segment, organic net sales declined 1.9% in Q2 2025, attributed to lost distribution in Digestive Health and Oral Care, which weighed on private label volumes (Perrigo Q2 Release).
Adjusted gross margin narrowed by 250 basis points to 38.1% in Q2 2025, affected by isolated production scrap in infant formula and reduced overhead absorption in OTC and Oral Care, highlighting ongoing margin pressures despite cost-saving efforts (Perrigo Q2 Release).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Perrigo Financial Performance
Revenues and expenses
Perrigo Earnings Performance
Company profitability
Perrigo News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Sept16
Perrigo
DividendPayment
$0.29Per share
FAQs
What’s the current market cap for Perrigo stock?
Perrigo (PRGO) has a market cap of $3.1B as of September 15, 2025.
What is the P/E ratio for Perrigo stock?
The price to earnings (P/E) ratio for Perrigo (PRGO) stock is 0 as of September 15, 2025.
Does Perrigo stock pay dividends?
Yes, the Perrigo (PRGO) stock pays dividends to shareholders. As of September 15, 2025, the dividend rate is $1.132 and the yield is 5.14%. Perrigo has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Perrigo dividend payment date?
The next Perrigo (PRGO) dividend payment is scheduled for September 16, 2025.
What is the beta indicator for Perrigo?
Perrigo (PRGO) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.